건강한 폐경기 여성에서 호르몬 대체요법이 경동맥 내중막두께에 미치는 영 = The Effect of Hormone Replacement Therapy on Carotid Intima-Media Thickness in Healthy Postmenopausal Women

다국어 초록 (Multilingual Abstract)

Background: Cardiovascular disease is the leading cause of death in postmenopausal women. The use of hormone replacement therapy (HRT) preventing for cardiovascular disease in postmenopausal women remains controversial. We investigated the effect of HRT on carotid intima-media thickness (IMT) according to the HRT duration in healthy postmenopausal women. Methods: One hundred and twenty postmenopausal women (mean age: 55.4 ± 3.3 years) were classified into never users, short-term, and long-term users according to the HRT duration. Carotid IMT was measured, and the clinical and biochemical cardiovascular risk factors were examined.Results: The mean IMT was significantly thinner in the long-term users than that in the never users (0.62 ± 0.11 vs. 0.71 ± 0.14 mm, P < 0.01). Also, the maximal IMT was significantly thinner in the short-term and the long-term users. However, there is no significant difference in the mean and maximal IMTs between the estrogen alone and estrogen plus progestins used group. The period exposed to menopause was significantly shorter in the long-term users than that in the never users (1.8 ± 2.3 vs. 4.3 ± 3.3 years, P < 0.001). Conclusion: Our findings suggest that if HRT is initiated during early postmenopausal period before the onset of atherosclerosis, HRT may have a beneficial effect on the prevention of carotid atherosclerosis (J Kor Soc Endocrinol 21:14~21, 2006).

국문 초록 (Abstract)

연구배경: 관상동맥질환은 폐경기 여성의 주된 사망 원인으로 알려져 있다. 현재 폐경기 여성에서 심혈관질환 예방을 위한 호르몬 대체요법의 사용은 논란의 여지가 많다. 이에 저자 등은 건강한 폐경기 여성에서 초음파를 이용하여 경동맥 내중막두께를 측정하여 투여기간에 따라 호르몬 대체요법이 경동맥 죽상경화증에 미치는 영향을 고찰하였다.방법: 심혈관질환의 과거력이 없는 50세에서 60세까지의 폐경기 여성 120명을 호르몬 대체요법 투여기간에 따라 투여 받지 않은 대조군 (52명), 3년 미만 투여군 (40명), 및 3년 이상 투여군 (28명)으로 분류하였다. 심혈관질환의 위험인자로 알려진 임상적 특성과 생화학적 인자를 측정하였으며, 경동맥 죽상경화증의 정도를 평가하기 위해 초음파를 이용하여 경동맥 내중막두께를 측정하였다.결과: 경동맥 내중막두께의 평균값은 대조군에 비해 3년 이상 투여군에서 유의하게 낮았다 (0.62 ± 0.11 vs. 0.71 ± 0.14 mm, P < 0.01). 또한, 경동맥 내중막두께의 최대값도 대조군에 비해 3년 미만 투여군 및 3년 이상 투여군에서 각각 유의하게 낮았다. 그러나 에스트로겐 단독투여군과 프로게스테론 병용투여군 간에 경동맥 내중막두께의 평균값 및 최대값은 유의한 차이를 보이지 않았다. 폐경에 노출된 기간은 3년 이상 투여군에서 대조군에 비해 유의하게 짧았다 (1.8 ± 2.3 vs. 4.3 ± 3.3 years, P < 0.001).

참고문헌 (Reference)

1 Rossouw JE, "Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women." 288 : 321-333, 2002

2 Hodis HN, "The role of carotid arterial intima-media thickness in predicting clinical coronary events" 128 : 262-269, 1998

3 Koh SCL, "The effects of long-term hormone replacement therapy on coagulation, fibrinolysis and inhibitors in postmeno- pausal women" 62 : 279-285, 1998

4 Koh KK, "Relation of fibrinolytic potentiation by estrogen to coagulation pathway activation in postmenopausal women" 83 : 466-469, 1999

5 Hulley S, "Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group" 280 : 605-613, 1998

6 Sullivan JM, "Postmenopausal estrogen use and coronary atherosclerosis" 108 : 358-363, 1988

7 Grodstein F, "Postmenopausal estrogen and progestin use and the risk of cardiovascular disease" 335 : 453-461, 1996

8 Stampfer MJ, "Postmeno- pausal estrogen therapy and cardiovascular disease.Ten-year follow-up from the Nurses’ Health Study" 325 : 756-762, 1991

9 Johansson S, "Myocardial infarction in women" 5 : 67-95, 1983

10 Colditz GA, "Menopause and the risk of coronary heart disease in women" 316 : 1105-1110, 1987

11 Kannel WB, "Menopause and risk of cardiovascular disease:the Framingham study" 85 : 447-452, 1976

12 Stampfer MJ, "Menopause and heart disease:a review" 592 : 193-203, 1990

13 Mendelsohn ME, "Mechanisms of disease:The protective effects of estrogen on the cardiovascular system" 340 : 1801-1811, 1999

14 American Heart Association, "Heart disease and stroke statistics-2000 update." 1999

15 Byington RP, "Heart and Estrogen/Progestin Replacement Study Research Group: Effect of estrogen plus progestin on progression of carotid atherosclerosis in postmenopausal women with heart disease: HERS B-mode substudy" 22 : 1692-1697, 2002

16 Li G, "Estrogen inhibits vascular smooth muscle cell- dependent adventitial fibroblast migration in vitro" 100 : 1639-1645, 1999

17 Hodis HN,, "Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial" 135 : 939-953, 2001

18 Mendelsohn ME, "Estrogen and the blood vessel wall" 9 : 619-626, 1994

19 Barrett-Connor E, "Estrogen and coronary heart disease in women" 265 : 1861-1867, 1991

20 Friedewald WT, "Estimation of the concentration of low-density lipoprotein cholesterol in plasma,without use of the preparative ultracentrifuge" 18 : 499-502, 1972

21 Godsland IF, "Effects of postmenopausal hormone replacement therapy on lipid analysis of studies published from 1974-2000" 75 : 898-915, 2001

22 Liang YL, "Effects of oestrogen and progesterone on age-related changes in arteries of postmenopausal women" 24 : 457-459, 1997

23 Koh KK, "Effects of hormone replacement therapy on plaque stability,inflammation,and fibrinolysis in hypertensive or overweight postmenopausal women" 88 : 1423-1426, 2001

24 Herrington DM, "Effects of estrogen replacement on the progression of coronary artery atherosclerosis" 343 : 522-529, 2000

25 The Writing Group for the PEPI Trial, "Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial." 273 : 199-208, 1995

26 Women's Health Initiative Steering Committee, "Effects of conjugated equine estrogen in postmenopausal women with hysterectomy." 291 : 1701-1712, 2004

27 Cushman M, "Effect of postmenopausal hormones on inflammation- sensitive proteins: The Postmenopausal Estrogen/ Progestin Interventions (PEPI) Study" 100 : 717-722, 1999

28 Jonas HA, "Current estrogen-progestin and estrogen replacement therapy in elderly women: association with carotid atherosclerosis. CHS Collaborative Research Group. Cardiovascular Health Study" 6 : 314-323, 1996

29 Bots ML, "Common carotid intima-media thickness and risk of stroke and myocardial infarction.the Rotterdam Study" 96 : 1432-1437, 1997

30 Manson JE, "Clinical practice:Postmeno- pausal hormone replacement therapy" 345 : 34-40, 2001

31 Sutton-Tyrrell K, "Carotid atherosclerosis in premenopausal and postmenopausal women and its association with risk factors measured after menopause" 29 : 1116-1121, 1998

32 Howard G, "Carotid artery intimal-medial thickness distribution in general populations as evaluated by B-mode ultrasound.ARIC Investigators" 9 : 1297-1304, 1993

33 Bush TL, "Cardiovascular mortality and non-contraceptive use of estrogen in women:results from the Lipid Research Clinics Program Follow-up Study" 75 : 1102-1109, 1987

34 Eaker ED, "Cardiovascular disease in women" 88 : 1999-2009, 1993

35 Burke GL, "Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults:the ARIC study" 26 : 386-391, 1995